Search

Your search keyword '"Hobbs, Leanne M"' showing total 7 results
Start Over Author "Hobbs, Leanne M"
7 results on '"Hobbs, Leanne M"'

1. The vaccinia‐based Sementis Copenhagen Vector COVID‐19 vaccine induces broad and durable cellular and humoral immune responses

Author

Eldi, Preethi, primary, Cooper, Tamara H, additional, Prow, Natalie A, additional, Liu, Liang, additional, Heinemann, Gary K, additional, Zhang, Voueleng J, additional, Trinidad, Abigail D, additional, Guzman‐Genuino, Ruth Marian, additional, Wulff, Peter, additional, Hobbs, Leanne M, additional, Diener, Kerrilyn R, additional, and Hayball, John D, additional

Published
2022
Full Text
View/download PDF

2. The vaccinia-based Sementis Copenhagen Vector COVID-19 vaccine induces broad and durable cellular and humoral immune responses

Author

Eldi, Preethi, primary, Cooper, Tamara H., additional, Prow, Natalie A., additional, Liu, Liang, additional, Heinemann, Gary K., additional, Zhang, Voueleng J., additional, Trinidad, Abigail D., additional, Guzman-Genuino, Ruth Marian, additional, Wulff, Peter, additional, Hobbs, Leanne M., additional, Diener, Kerrilyn R., additional, and Hayball, John D., additional

Published
2021
Full Text
View/download PDF

3. The vaccinia‐based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses.

Author

Eldi, Preethi, Cooper, Tamara H, Prow, Natalie A, Liu, Liang, Heinemann, Gary K, Zhang, Voueleng J, Trinidad, Abigail D, Guzman‐Genuino, Ruth Marian, Wulff, Peter, Hobbs, Leanne M, Diener, Kerrilyn R, and Hayball, John D

Subjects
COVID-19, SARS-CoV-2, DISEASE vectors, CYTOTOXIC T cells
Abstract

The ongoing coronavirus disease 2019 (COVID‐19) pandemic perpetuated by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants has highlighted the continued need for broadly protective vaccines that elicit robust and durable protection. Here, the vaccinia virus‐based, replication‐defective Sementis Copenhagen Vector (SCV) was used to develop a first‐generation COVID‐19 vaccine encoding the spike glycoprotein (SCV‐S). Vaccination of mice rapidly induced polyfunctional CD8 T cells with cytotoxic activity and robust type 1 T helper‐biased, spike‐specific antibodies, which are significantly increased following a second vaccination, and contained neutralizing activity against the alpha and beta variants of concern. Longitudinal studies indicated that neutralizing antibody activity was maintained up to 9 months after vaccination in both young and middle‐aged mice, with durable immune memory evident even in the presence of pre‐existing vector immunity. Therefore, SCV‐S vaccination has a positive immunogenicity profile, with potential to expand protection generated by current vaccines in a heterologous boost format and presents a solid basis for second‐generation SCV‐based COVID‐19 vaccine candidates incorporating additional SARS‐CoV‐2 immunogens. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

7. The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses

Author

Preethi Eldi, Tamara H Cooper, Natalie A Prow, Liang Liu, Gary K Heinemann, Voueleng J Zhang, Abigail D Trinidad, Ruth Marian Guzman‐Genuino, Peter Wulff, Leanne M Hobbs, Kerrilyn R Diener, John D Hayball, Eldi, Preethi, Cooper, Tamara H, Prow, Natalie A, Liu, Liang, Heinemann, Gary K, Zhang, Voueleng J, Trinidad, Abigail D, Guzman-Genuino, Ruth Marian, Wulff, Peter, Hobbs, Leanne M, Diener, Kerrilyn R, and Hayball, John D

Subjects
Immunity, Cellular, COVID-19 Vaccines, SARS-CoV-2, Vaccination, Immunology, COVID-19, Cell Biology, spike, Antibodies, Viral, cellular responses, Antibodies, Neutralizing, Immunity, Humoral, Mice, polyfunctional T cells, vaccine, Spike Glycoprotein, Coronavirus, Vaccinia, Animals, Humans, Immunology and Allergy, antibodies
Abstract

Refereed/Peer-reviewed The ongoing coronavirus disease 2019 (COVID-19) pandemic perpetuated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has highlighted the continued need for broadly protective vaccines that elicit robust and durable protection. Here, the vaccinia virus-based, replication-defective Sementis Copenhagen Vector (SCV) was used to develop a first-generation COVID-19 vaccine encoding the spike glycoprotein (SCV-S). Vaccination of mice rapidly induced polyfunctional CD8 T cells with cytotoxic activity and robust type 1 T helper-biased, spike-specific antibodies, which are significantly increased following a second vaccination, and contained neutralizing activity against the alpha and beta variants of concern. Longitudinal studies indicated that neutralizing antibody activity was maintained up to 9 months after vaccination in both young and middle-aged mice, with durable immune memory evident even in the presence of pre-existing vector immunity. Therefore, SCV-S vaccination has a positive immunogenicity profile, with potential to expand protection generated by current vaccines in a heterologous boost format and presents a solid basis for second-generation SCV-based COVID-19 vaccine candidates incorporating additional SARS-CoV-2 immunogens.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results